Bristol-Myers Squibb 4Q Revenues: $5.2 billion (+22%) 4Q Earnings: $894 million (loss of $197 million 4Q15) FY Revenues: $19.4 billion (+17%) FY Earnings: $4.5 billion (earnings were $1.6 billion FY15) Comments: Growth was driven by key products, Opdivo, with $3.8 billion in sales, up from $942 million FY15, and Eliquis, with sales of $3.3 billion, up 80%. Sprycel sales were up 13% to $1.8 billion. Yervoy sales were down 6% to $1.1 billion. Virology sales slipped for the company’s...